PYXS
Pyxis Oncology, Inc.
There isn't enough reported data to score PYXS yet.
PYXS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PYXS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
PYXS PE Valuation
PYXS has no meaningful PE right now: it lost money over the past year.
PYXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PYXS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PYXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.29 | +$0.33 |
| Q2 2026 | -$1.40 | +$0.22 |
| Q1 2026 | -$1.30 | +$0.31 |
| Q4 2025 | -$1.28 | +$0.04 |
| Q3 2025 | -$1.62 | -$0.58 |
| Q2 2025 | -$1.62 | -$0.37 |
| Q1 2025 | -$1.61 | -$0.24 |
| Q4 2024 | -$1.32 | +$0.53 |
PYXS is still losing money, but far less than before: $1.29 per share over the past year, against $3.65 at its worst in late 2022.
PYXS Quarterly Revenue
PYXS's revenue has slid since its 2024 peak: $11M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -166% | N/A |
| Q2 2025 | -700% | N/A |
| Q1 2024 | -35% | N/A |
PYXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$10.4M | +$8.9M |
| Q4 2024 | -$19.3M | -$4M |
| Q3 2024 | -$14.7M | +$3M |
| Q2 2024 | -$3M | +$10.3M |
| Q1 2024 | -$20.9M | +$10.3M |
| Q4 2023 | -$15.3M | +$4M |
| Q3 2023 | -$17.6M | +$7.2M |
| Q2 2023 | -$13.3M | +$10.6M |
PYXS has burned cash in almost every quarter: −$74M over the past year, against −$54M the year before.
PYXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +30% | +19.5M shares |
| 1 year | +33% | +21M shares |
| 3 years | +118% | +45.1M shares |
| 5 years | +277% | +61.4M shares |
PYXS has 84M diluted shares, up 33% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PYXS Net Leverage
PYXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PYXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.4 | Neutral |
| Stochastic | 5.4 | Oversold |
PYXS's weekly RSI is 40 (neutral) and its Stochastic is 5 (oversold).
PYXS PE vs Healthcare Sector
PYXS has no meaningful PE right now: it lost money over the past year.
PYXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.93 | 18% below |
| 20 week MA | $2.59 | 39% below |
| 50 week MA | $2.15 | 27% below |
| 100 week MA | $1.97 | 20% below |
| 200 week MA | $2.50 | 37% below |
PYXS is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
PYXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $13.2 | $9.81 | -26% |
| 2022 | $9.81 | $1.28 | -87% |
| 2023 | $1.28 | $1.80 | +41% |
| 2024 | $1.80 | $1.59 | -12% |
| 2025 | $1.59 | $1.11 | -30% |
| 2026 YTD | $1.11 | $1.58 | +42% |
PYXS is up 42% so far in 2026, after finishing lower in four of the previous five years.